Ventilator-associated respiratory infection in a resource-restricted setting: impact and etiology
Authors:
- Vu Dinh PhuVPVu Dinh Phu
- Behzad NadjmBNBehzad Nadjm
- Nguyen Hoang Anh DuyNDNguyen Hoang Anh Duy
- Dao Xuan CoDCDao Xuan Co
- Nguyen Thi Hoang MaiNMNguyen Thi Hoang Mai
- Dao Tuyet TrinhDTDao Tuyet Trinh
- James CampbellJCJames Campbell
- Dong Phu KhiemDKDong Phu Khiem
- Tran Ngoc QuangTQTran Ngoc Quang
- Huynh Thi LoanHLHuynh Thi Loan
- Ha Son BinhHBHa Son Binh
- Quynh-Dao DinhQDQuynh-Dao Dinh
Open Access
- 19 December 2017
- journal article
- research article
- Published by Springer Nature in Journal of Intensive Care
- Vol. 5 (1) , 69
Abstract
Ventilator-associated respiratory infection (VARI) is a significant problem in resource-restricted intensive care units (ICUs), but differences in casemix and etiology means VARI in resource-restricted ICUs may be different from that found in resource-rich units. Data from these settings are vital to plan preventative interventions and assess their cost-effectiveness, but few are available. We conducted a prospective observational study in four Vietnamese ICUs to assess the incidence and impact of VARI. Patients ≥ 16 years old and expected to be mechanically ventilated > 48 h were enrolled in the study and followed daily for 28 days following ICU admission. Four hundred fifty eligible patients were enrolled over 24 months, and after exclusions, 374 patients’ data were analyzed. A total of 92/374 cases of VARI (21.7/1000 ventilator days) were diagnosed; 37 (9.9%) of these met ventilator-associated pneumonia (VAP) criteria (8.7/1000 ventilator days). Patients with any VARI, VAP, or VARI without VAP experienced increased hospital and ICU stay, ICU cost, and antibiotic use (p < 0.01 for all). This was also true for all VARI (p < 0.01 for all) with/without tetanus. There was no increased risk of in-hospital death in patients with VARI compared to those without (VAP HR 1.58, 95% CI 0.75–3.33, p = 0.23; VARI without VAP HR 0.40, 95% CI 0.14–1.17, p = 0.09). In patients with positive endotracheal aspirate cultures, most VARI was caused by Gram-negative organisms; the most frequent were Acinetobacter baumannii (32/73, 43.8%) Klebsiella pneumoniae (26/73, 35.6%), and Pseudomonas aeruginosa (24/73, 32.9%). 40/68 (58.8%) patients with positive cultures for these had carbapenem-resistant isolates. Patients with carbapenem-resistant VARI had significantly greater ICU costs than patients with carbapenem-susceptible isolates (6053 USD (IQR 3806–7824) vs 3131 USD (IQR 2108–7551), p = 0.04) and after correction for adequacy of initial antibiotics and APACHE II score, showed a trend towards increased risk of in-hospital death (HR 2.82, 95% CI 0.75–6.75, p = 0.15). VARI in a resource-restricted setting has limited impact on mortality, but shows significant association with increased patient costs, length of stay, and antibiotic use, particularly when caused by carbapenem-resistant bacteria. Evidence-based interventions to reduce VARI in these settings are urgently needed.Keywords
Funding Information
- Wellcome Trust
- Li Ka Shing Foundation
- Swedish International Development Agency
This publication has 37 references indexed in Scilit:
- Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the futureIntensive Care Medicine, 2017
- From starting mechanical ventilation to ventilator-associated pneumonia, choosing the right moment to start antibiotic treatmentCritical Care, 2016
- Burden of Hospital Acquired Infections and Antimicrobial Use in Vietnamese Adult Intensive Care UnitsPLOS ONE, 2016
- Comparison between a clinical diagnosis method and the surveillance technique of the Center for Disease Control and Prevention for identification of mechanical ventilator-associated pneumoniaRevista Brasileira de Terapia Intensiva, 2015
- Ventilator-Associated Pneumonia: Epidemiology and Prognostic Indicators of 30-Day MortalityJapanese Journal of Infectious Diseases, 2015
- National Healthcare Safety Network (NHSN) report, data summary for 2012, Device-associated moduleAmerican Journal of Infection Control, 2013
- Incidence and Outcomes of Ventilator-associated Tracheobronchitis and PneumoniaThe American Journal of Medicine, 2013
- The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial useEurosurveillance, 2012
- Ventilator-associated pneumonia in adults in developing countries: a systematic reviewInternational Journal of Infectious Diseases, 2008
- Ventilator-associated PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2002